CGC-11047

DB05722InvestigationalSmall molecule

CGC-11047 is a polyamine analog designed to halt cell growth and induce apoptosis.

Mechanism: The mechanism of action of CGC-11047 is unknown but it is believed to block the growth of cancer cells by blocking the production of new DNA in the cancer cells.
Curator reviewed
Primary indication: Investigated for use/treatment in lymphoma (unspecified), macular degeneration, prostate cancer, and solid tumors.Curator reviewed
Formula / weight: C₁₄H₃₉Cl₇N₄ · 511.64 g/mol (avg)
Code names: CGC-11047 · SL 11047 · SL 47

Resolves to

Compound

Structure

InChIKeyMNJCMBNLXQCNHO-YGGCHVFLSA-NSMILESCl.Cl.Cl.Cl.CCNCCCNC\C=C/CNCCCNCC

What you can answer from here — as of May 10, 2021

3Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which companies are running trials of CGC-11047, in which indications and phases, and which of those programs are still active?

Create a free account or log in to explore the full data card.